{"filings":[{"id":1537516,"accession_number":"0001193125-26-299290","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-07-09T13:31:32+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"FibroBiologics appoints former NASA astronaut Kathleen Rubins to board; director Matt Link resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matt Link resigned from the board effective July 2, 2026.","Kathleen Rubins appointed as Class III director effective July 8, 2026, term until 2029 annual meeting.","Rubins also appointed to Audit, Compensation, and Governance Committees.","Rubins is a retired NASA astronaut, microbiologist, and founding director of Trivedi Institute at University of Pittsburgh.","She previously served on FibroBiologics' Scientific Advisory Board since 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1333518,"accession_number":"0001193125-26-288468","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-06-29T20:15:37+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"FibroBiologics closes $3M private placement; warrants could add $6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $3.0M from sale of 4.08M shares/pre-funded warrants + warrants at $0.735/share.","Net proceeds ~$2.6M; warrants exercisable only after stockholder approval for up to 8.16M additional shares.","If all warrants exercised for cash, total gross proceeds could reach ~$9.0M.","H.C. Wainwright acted as placement agent, receiving 7% cash fee and 285,714 placement agent warrants.","Funds earmarked for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1224559,"accession_number":"0001193125-26-279778","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-06-23T21:16:01+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"FibroBiologics annual meeting approves 2026 equity plan, re-elects director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved the 2026 Equity and Incentive Plan with 2.62M for, 297k against; 2.06M shares available, including 2M new shares and 61,968 from prior plan.","Pete O'Heeron re-elected as Class III director with 2.80M for, 119k against; Stacy Coen did not stand for re-election.","Ratified WithumSmith+Brown as auditor for FY 2026 with 4.11M for, 43k against.","Approved issuance of up to 2.27M shares from March SPA warrants and 159k shares from H.C. Wainwright engagement letter.","4.17M shares represented out of 6.83M eligible; all four proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96935,"accession_number":"0001193125-26-207530","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"FibroBiologics ups ATM offering to $7.5M; 71,830 shares sold to date","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased maximum aggregate offering price under ATM facility to $7.5 million.","71,830 shares of common stock sold to date under Sales Agreement with H.C. Wainwright & Co.","ATM offering uses existing S-3 shelf registration (effective Feb 10, 2025); prospectus supplement filed May 5, 2026.","Legal opinion and consent of Sichenzia Ross Ference Carmel LLP filed as exhibits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96934,"accession_number":"0001193125-26-205044","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"FibroBiologics grants stock options to four top executives at $1.38 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Pete O'Heeron granted options for 92,410 shares; CFO, CSO, and General Counsel each granted 61,607 shares.","Vesting: 1/4th on first anniversary, then monthly over 36 months, subject to continuous service.","Total of 277,231 stock options granted under the 2022 Stock Plan on May 4, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96933,"accession_number":"0001193125-26-201376","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"FibroBiologics enters $6.15M ATM offering with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $6.15M of common stock may be sold via at-the-market offering with H.C. Wainwright.","H.C. Wainwright receives 3.0% commission on gross proceeds plus $100K legal reimbursement.","Net proceeds used for working capital and general corporate purposes.","Shares will be sold under existing S-3 shelf (Reg. No. 333-284663).","Company not obligated to sell any shares; no assurance on price or timing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96932,"accession_number":"0001193125-26-164018","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FibroBiologics regains full compliance with Nasdaq listing requirements; monitoring periods imposed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq confirmed compliance with $2.5M stockholders' equity rule (Mar 9) and $1.00 bid price rule (Apr 17).","One-year Mandatory Panel Monitor for both equity and bid price; failure during monitor triggers delist determination without cure period.","Company remains listed on Nasdaq Capital Market under symbol FBLG; all prior listing matters closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96931,"accession_number":"0001193125-26-161507","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"FibroBiologics amends bylaws to reduce stockholder quorum to one-third of voting power","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board amended Section 2.07 of Bylaws to lower quorum from majority to one-third of voting power.","Amendment adopted on April 16, 2026, and effective immediately.","No other material items reported in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96930,"accession_number":"0001193125-26-149654","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"FibroBiologics terminates sublease early, saves ~$0.8M in rent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sublease for Webster, TX office terminated April 2, 2026, 18 months early; single payment of $45,108.25 resolves all rent obligations.","Company expects to save approx. $0.8 million in future rent payments through consolidation.","New principal executive office address is 9350 Kirby Drive, Suite 300, Houston, TX 77054, following 2025 opening of 10,000+ sq ft lab."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96927,"accession_number":"0001193125-26-149865","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K/A","filed_at":"2026-04-09T23:59:59+00:00","items":["1.02","1.01","8.01","9.01"],"status":"ready","headline":"FibroBiologics terminates sublease early, saves $0.8M in future rent; moves HQ to Houston","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sublease buyout agreement with United Fire & Casualty terminates sublease effective April 2, 2026, 18 months early.","Single exit payment of $45,108.25 resolves remaining rent obligations; original sublease ran through Nov 30, 2027.","Expected savings of approx. $0.8 million in future rent payments.","Consolidation follows 2025 opening of new 10,000+ sq ft lab and office facility.","Principal executive offices relocated to 9350 Kirby Drive, Suite 300, Houston, TX 77054."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96929,"accession_number":"0001193125-26-142089","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"FibroBiologics implements 1-for-20 reverse stock split effective March 30, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio of 1:20; every 20 shares converted to 1 share.","No fractional shares issued; any fractional interests rounded up to the nearest whole share.","Par value unchanged at $0.00001; authorized shares unchanged.","CUSIP changed to 31573L204; trading symbol remains 'FBLG'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96928,"accession_number":"0001193125-26-140044","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"FibroBiologics closes $3M public offering of common stock and warrants at $1.32/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 2,272,728 shares (or pre-funded warrants) plus warrants, combined price $1.32/unit; net proceeds ~$2.5M after fees.","Warrants exercise price $1.32, exercisable only after stockholder approval; if fully cash-exercised, additional $3M proceeds possible.","Pre-funded warrants exercise price $0.00001, no expiration; beneficial ownership cap 9.99%.","Placement agent H.C. Wainwright received 7.0% cash fee, 1.0% management fee, and 159,091 placement agent warrants at $1.65.","Lock-up: insiders 30 days; company restricted from further equity issuance for 30 days and no variable-rate transactions for one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111300,"accession_number":"0001193125-26-096474","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"FibroBiologics raises CFO Jason D. Davis base salary to $400,000","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO Jason D. Davis annual base salary increased to $400,000, effective January 1, 2026.","Target non-equity incentive compensation remains at 40% of base salary.","No other changes to CFO compensation or role were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111299,"accession_number":"0001193125-26-064040","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"FibroBiologics stockholders approve reverse stock split and warrant issuances","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split approved at ratio between 1:5 and 1:30, with board discretion; 53.6M votes for, 1.3M against.","Issuance of up to 12.1M shares upon exercise of warrants from Nov 18, 2025 SPA approved (47.9M for, 1.2M against).","Issuance of up to 4.8M shares upon exercise of warrants from Nov 24, 2025 SPA and related engagement letter approved.","Issuance of up to 5.6M shares upon exercise of warrants from Dec 14, 2025 SPA and related engagement letter approved.","Adjournment proposal also passed; all five proposals approved at Feb 20, 2026 special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111298,"accession_number":"0001193125-26-041187","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"FibroBiologics receives Nasdaq delisting notice for continued MVLS non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified FibroBiologics on Feb 3, 2026 that continued failure to meet the $35M MVLS minimum adds a delisting basis.","The Panel will consider the company's plan to regain compliance with both the bid price and MVLS rules at a hearing.","FibroBiologics filed a proxy seeking shareholder approval for a reverse stock split (1:5 to 1:30) to address bid price deficiency.","Trading continues pending the Panel's decision; no assurance of an extension or successful compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111297,"accession_number":"0001193125-26-001077","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"FibroBiologics receives Nasdaq delisting notice for bid price non-compliance; plans hearing and reverse split vote","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified delisting on Dec 30, 2025, after 180-day cure period ended Dec 29 without compliance.","Company plans to request a hearing before the Nasdaq Hearings Panel to stay delisting.","Proxy filed Dec 29 seeking stockholder approval for reverse stock split (1-for-5 to 1-for-30).","No assurance of extension or successful regaining of compliance with $1.00 bid price rule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127906,"accession_number":"0001193125-25-319441","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"FibroBiologics raises ~$1.7M in registered direct offering at $0.33/share with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 5,227,275 shares at $0.33/share; gross proceeds ~$1.7M; closing expected Dec 16, 2025.","Concurrent private placement of warrants to buy 5,227,275 shares at $0.33, exercisable only after stockholder approval, 5-year term.","CEO and prior purchaser entered voting agreements to support warrant share issuance under Nasdaq rules.","Placement agent H.C. Wainwright receives 7% cash fee and 365,909 warrants at $0.4125 per share.","Net proceeds for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127905,"accession_number":"0001193125-25-294634","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"FibroBiologics raises $1.5M in registered direct offering priced at $0.335/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 4,477,614 shares at $0.335/share; gross proceeds ~$1.5M before fees.","Concurrent private placement of 4,477,614 warrants at $0.335 exercise price; exercisable upon stockholder approval.","H.C. Wainwright placement agent gets 7.0% cash fee, 1.0% management fee, and 313,433 placement agent warrants at $0.4188.","Net proceeds for working capital and general corporate purposes.","30-day lock-up on equity issuances; one-year ban on Variable Rate Transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127904,"accession_number":"0001193125-25-288264","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"FibroBiologics raises ~$4M in registered direct offering paid in gold coins; redeems $3.4M note","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 3,540,000 shares and 8,570,203 pre-funded warrants at $0.3303/unit, gross proceeds ~$4M.","Payment in sovereign-issued .9999 fine gold coins valued at $4,069.18/oz, intent to liquidate to USD.","Concurrent private placement of 12,110,203 warrants at $0.3303, exercisable after stockholder approval.","Redeemed final Promissory Note (third tranche) of $3.4M principal plus 6% premium for total $3.604M.","Net proceeds for general corporate purposes, including debt satisfaction; offering closes Nov. 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144678,"accession_number":"0000950170-25-105807","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"FibroBiologics receives Nasdaq MVLS deficiency notice; 180-day cure period to Feb 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified FibroBiologics on Aug 4, 2025 that its MVLS fell below the $35M minimum for continued listing.","Company has until Feb 2, 2026 to regain compliance by having MVLS close at $35M+ for 10 consecutive business days.","No immediate impact on listing; stock continues trading on Nasdaq Capital Market under symbol FBLG.","If compliance is not regained by Feb 2, 2026, Nasdaq may initiate delisting, subject to appeal.","Company will monitor MVLS and consider available options to address the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144677,"accession_number":"0000950170-25-096914","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"FibroBiologics converts $1.4M of notes, issues 2.15M shares at ~$0.65 avg price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On June 20-27 and July 15, 2025, YA II PN converted $1.4M of Second and Third Notes into 2,154,530 common shares.","Conversion prices ranged from $0.5624 to $0.6934 per share; Second Note fully converted, Third Note has $3.9M remaining.","First Note retains full $5.0M principal; total remaining note balance across all three is $8.9M.","Shares issued in reliance on Section 4(a)(2) exemption; no public offering involved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144675,"accession_number":"0000950170-25-096923","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K/A","filed_at":"2025-07-18T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"FibroBiologics amends 8-K to disclose up to 41.4M shares issuable under SEPA with YA II PN","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maximum shares convertible from $15M promissory notes: 36,945,812 shares at $0.406/share.","Additional maximum shares from Commitment Amount: 4,424,778 shares at $2.26/share.","Agreement with YA II PN, Ltd. was previously disclosed on Dec 20, 2024; amendment adds share counts.","Conversion price subject to anti-dilution adjustments; shares unregistered under Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144676,"accession_number":"0000950170-25-093832","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"FibroBiologics receives Nasdaq bid price deficiency notice; 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified FibroBiologics on July 1, 2025 that common stock closing bid price was below $1.00 for 30 consecutive trading days.","Company has until December 29, 2025 to regain compliance by maintaining $1.00+ closing bid for 10 consecutive business days.","If not cured by deadline, FibroBiologics may qualify for a second 180-day period subject to meeting other listing standards.","Failure to cure could lead to delisting; Company may consider options to regain compliance, no guarantee of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163080,"accession_number":"0001641172-25-015282","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"FibroBiologics closes $5M third tranche of $25M SEPA with Yorkville; funds for R&D and diabetic foot ulcer trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Third $5M tranche of $15M pre-paid advance drawn; total $15M now under SEPA with YA II PN, Ltd.","Convertible promissory note: 0% interest (18% on default), matures Dec 20, 2025, convertible at lower of $0.9801 or 94% of 5-day VWAP.","Proceeds for general corporate purposes, including R&D and Phase 1/2 diabetic foot ulcer trial expected H2 2025.","Company may sell additional $10M common stock to Yorkville with consent while notes outstanding.","Conversion limited to 4.99% beneficial ownership cap; prior conversions totaled $5.7M principal at varying prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163079,"accession_number":"0001641172-25-015065","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"FibroBiologics stockholders approve capital stock increase and share issuance to YA II PN","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized capital stock increased via amendment to certificate of incorporation effective June 12, 2025.","Stockholders elected Matthew Link and Victoria Niklas, M.D. as Class II directors until 2028.","Ratified WithumSmith+Brown, PC as independent auditor for FY 2025; votes: 53,940,908 for, 73,899 against, 528,109 abstain.","Approved issuance of common stock to YA II PN, LTD., exceeding 7,013,635 shares under Standby Equity Purchase Agreement.","Proxies representing 54,542,916 votes (77.4% of eligible) were present at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163078,"accession_number":"0001641172-25-014296","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"FibroBiologics appoints Jason D. Davis, CPA, as CFO; base salary $350k","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason D. Davis appointed CFO effective June 9, 2025; previously CFO at Virax Biolabs, led IPO in July 2022.","Employment agreement includes base salary of $350k, annual bonus up to 40% of base, and sign-on cash bonus of $15k.","Received option grant of 450,000 shares under 2022 Stock Plan; vests 1/4 on first anniversary, then monthly.","Davis has 20+ years finance experience; at HyperDynamics increased market cap from $20M to $700M and raised $200M+.","Appointment comes as FibroBiologics advances toward Phase 1/2 clinical trial for diabetic foot ulcers in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163077,"accession_number":"0001641172-25-008680","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"FibroBiologics Interim CFO Robert Hoffman resigns effective May 14, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert E. Hoffman resigned as Interim CFO effective May 14 to pursue another opportunity.","Hoffman will remain on the Board of Directors as a Class I director.","Company will initiate a search for a new CFO successor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180985,"accession_number":"0001493152-25-005456","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"FibroBiologics issues shares under $15M SEPA; converts $2.9M note principal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 118,991 shares as commitment fee at $2.1010/share on Jan 7, 2025.","Investor converted $900K, $500K, $500K, and $1.1M of Second Note between Jan 23 and Feb 7.","Conversion prices ranged $1.4955 to $1.6301; total shares issued: 1,936,628.","Second Note remaining principal is $2.0M as of Feb 7, 2025.","Sale relied on Section 4(a)(2) exemption; no public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180984,"accession_number":"0001493152-25-003571","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"FibroBiologics board approves 2024 incentive bonuses for CEO O'Heeron and other executives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Pete O'Heeron received $390,000 non-equity incentive bonus, total compensation $1,805,199 for 2024.","CSO Hamid Khoja received $150,000 bonus, total compensation $853,646.","GC Ruben Garcia (hired March 2024) received $142,188 bonus, total compensation $2,752,843 including option grant.","Interim CFO Robert Hoffman awarded a $75,000 bonus for 2024.","Bonuses were previously undetermined and approved on January 23, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197860,"accession_number":"0001493152-24-052707","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2024-12-31T23:59:59+00:00","items":["1.01","2.03","3.02","5.02","7.01","9.01"],"status":"ready","headline":"FibroBiologics closes $5M second tranche of convertible note; grants CEO/CSO options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second $5M tranche under SEPA with YA II PN (Yorkville) funded Dec 30, 2024; convertible note bears 0% interest (18% on default).","Conversion price is lower of $2.84/share or 94% of 5-day VWAP (with floor). Matures Dec 20, 2025; extendable by the company.","Company granted CEO Pete O'Heeron options for 406,339 shares and CSO Hamid Khoja options for 176,200 shares at $2.36/share.","Options vest 1/4 on Dec 27, 2025, then monthly over 36 months; issued under 2022 Stock Plan.","Net proceeds from the SEPA (up to $25M over 2 years) will be used for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197859,"accession_number":"0001493152-24-051209","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"FibroBiologics secures up to $25M standby equity facility with Yorkville; first $5M funded","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Yorkville advanced $5M initial tranche of $15M pre-paid convertible notes; two additional $5M tranches subject to conditions.","Conversion price lower of $2.41/share or 94% of 5-day VWAP; 0% interest (18% upon default), matures Dec 2025.","Additional $10M common stock purchase commitment available under SEPA over two years, subject to Yorkville's consent.","CEO states proceeds will fund first-in-human diabetic foot ulcer trial and psoriasis IND-enabling studies.","Shareholder approval required for issuances exceeding 19.99% of outstanding shares (Exchange Cap)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197858,"accession_number":"0001493152-24-051109","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["1.01","1.02","3.02","9.01"],"status":"ready","headline":"FibroBiologics issues 1.15M shares at $2.17, terminates GEM SPA and warrant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,152,074 shares to GEM at $2.17/share for aggregate $2.5M.","GEM waived remaining $1.5M commitment fee and terminated outstanding warrant.","Share purchase agreement with GEM terminated effective December 20, 2024.","Shares issued in private placement exempt from registration under Section 4(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197857,"accession_number":"0001493152-24-042867","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"CFO Mark Andersen resigns; Board member Robert Hoffman appointed Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Andersen resigns as CFO effective up to Nov 15, 2024; will transition duties.","Robert Hoffman, current Board member, appointed Interim CFO effective Oct 30, 2024.","Hoffman receives $45,833/month cash compensation; steps down from Audit/Compensation Committees.","Richard Cilento becomes Audit Committee Chairman; Stacy Coen joins Audit; Matthew Link leads Compensation Committee.","Andersen eligible for nine months base salary severance plus COBRA reimbursement on signing release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214046,"accession_number":"0001493152-24-037948","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"FibroBiologics enters 5-year MSA with Charles River Labs for development and manufacturing services","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Master Services Agreement with Charles River Laboratories effective September 19, 2024.","Term expires September 19, 2029; services and fees set via future Statements of Work.","Covers development and CDMO services including cell/gene therapy products.","Either party can terminate on 90 days' notice; material breach cure period also 90 days.","Standard confidentiality, IP, warranty, and indemnity terms; financial caps redacted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214045,"accession_number":"0001493152-24-034182","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"FibroBiologics' shareholders approve capital stock decrease, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected Richard Cilento and Robert Hoffman as Class I directors for terms expiring 2027; both received over 47M votes for.","Capital Decrease Amendment to reduce authorized capital stock approved with ~48.2M for, 11K against; filed Aug 27.","Clarifying Amendment to eliminate obsolete provisions approved; Amended and Restated Certificate of Incorporation effective Aug 27.","WithumSmith+Brown ratified as independent auditor for FY2024 with 54.95M for votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214044,"accession_number":"0001493152-24-034006","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2024-08-27T23:59:59+00:00","items":["3.02","7.01","9.01"],"status":"ready","headline":"FibroBiologics reports $3.9M gross proceeds from GEM equity line draw downs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Aug 26, 2024, sold 100,000 shares at net $4.51 (10% discount), gross $451K.","Prior draw down: 840,000 shares at net $4.09, gross $3,436K; 560,000 shares returned for cancellation.","Aggregate gross proceeds from GEM SPA subsequent to June 30, 2024: $3,887K.","Remaining 1,500,000 shares from July 12 draw down returned to Company and cancelled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233268,"accession_number":"0001493152-24-025365","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"FibroBiologics Amends Bylaws to Align with Universal Proxy Rules and DGCL Updates","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Amended bylaws adopted June 25, 2024, clarifying procedural requirements under Rule 14a-19 universal proxy rules.","Requires stockholders soliciting proxies to use a proxy card color other than white.","Raised threshold for stockholder amendments of bylaws to 66 2/3% to align with the Certificate of Incorporation.","Removed inconsistent provisions including ability of majority stockholders to remove directors without cause and call special meetings.","Eliminated duplicative and obsolete provisions such as stock transfer restrictions from the direct listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233267,"accession_number":"0001493152-24-016069","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FibroBiologics pipeline update: CYWC628 pre-clinical data shows improved wound healing vs Grafix","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CYWC628 multiple administration study: 69.3% wound area reduction at day 12 vs 47.13% for Grafix (p<0.05).","Planning Phase 1/2 clinical trial in Australia for diabetic foot ulcers in 2025, results expected Q3 2025.","FDA IND clearance for CybroCell Phase 1/2 trial for degenerative disc disease, conditional on master cell bank.","Expect to complete remaining CYWC628 pre-clinical studies (toxicity, dose titration) in Q3 2024.","Manufacturing: planning CDMO transfer; master cell bank, working cell bank, and drug product by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251393,"accession_number":"0001493152-24-007147","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FibroBiologics to present MS data at ACTRIMS; phase 0/1 shows safety, no adverse events","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 0/1 safety trial of allogeneic HDFs in 5 MS patients: no adverse events, strong CBC/blood chemistry/ECG correlation.","In vivo EAE model: HDFs suppressed Th17, expanded Tregs, stimulated remyelination, outperformed adipose/bone marrow MSCs.","Company designing phase II trial to test various HDF spheroid doses and multiple-dose treatments over 18 months.","Presentation at ACTRIMS Forum 2024 on Feb 29 in West Palm Beach, FL (poster P341)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251392,"accession_number":"0001493152-24-006266","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FibroBiologics preclinical data: HDF spheroids cut psoriasis severity 35% in mice","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Presented at 2024 Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases.","Single IV dose of HDF spheroids reduced average PASI score by 35% (p<0.0001) in IMQ-induced psoriasis mouse model.","Spheroids also ameliorated IMQ-induced spleen enlargement and normalized lymphocyte and monocyte counts.","In vitro, HDFs inhibited TNF-α and IL-17 and suppressed dendritic cell maturation via CD40/CD80/CD86 downregulation.","Company holds 150+ issued/pending patents; data supports IND-enabling studies for early-discovery psoriasis program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251391,"accession_number":"0001493152-24-005398","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FibroBiologics announces three US patents for fibroblast technology","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patent 11,717,596 (Sevrain): Methods for cartilage repair using in vivo bioreactor.","Patent 11,732,239 (O'Heeron): Treatment of disc degenerative disease with fibroblast conditioned media.","Patent 11,819,555 (O'Heeron): Gene therapy for regeneration of chondrocytes or cartilage-type cells.","Company now holds 150+ patents issued and pending, reinforcing its IP portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251390,"accession_number":"0001493152-24-005108","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FibroBiologics receives three Japanese patents for fibroblast therapy technology","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Japan Patent Office issued patents 7333272, 7386162, and 7387603, all invented by CEO Pete O'Heeron.","Patents cover methods enhancing fibroblast therapeutic activity, regenerative activity, and fibroblast-immune cell interaction.","Expands FibroBiologics' IP portfolio in Japan, a key cell therapy market.","Company is clinical-stage, focused on fibroblast-derived therapeutics for chronic diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251389,"accession_number":"0001493152-24-004643","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FibroBiologics begins trading on Nasdaq via direct listing under ticker FBLG","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Direct listing commenced January 31, 2024 on the Nasdaq Global Market.","Stock trades under ticker symbol FBLG.","Company is a clinical-stage biotech focused on fibroblast-based therapies for chronic diseases.","Registration statement on Form S-1 declared effective by SEC on January 24, 2024.","No financial results or operational milestones were disclosed in the announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5529263.462053572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}